Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Pharmagreen Biotech's share price for the quarter that ended in Jun. 2023 was $0.00175. Pharmagreen Biotech's Shares Outstanding (EOP) for the quarter that ended in Jun. 2023 was 463.96 Mil. Therefore, Pharmagreen Biotech's market cap for the quarter that ended in Jun. 2023 was $0.81 Mil.
Pharmagreen Biotech's quarterly market cap
increased
from Dec. 2022 ($1.41 Mil) to Mar. 2023 ($2.18 Mil) but then
declined
from Mar. 2023 ($2.18 Mil) to Jun. 2023 ($0.81 Mil).
Pharmagreen Biotech's annual market cap
increased
from Sep. 2020 ($7.66 Mil) to Sep. 2021 ($10.48 Mil) but then
declined
from Sep. 2021 ($10.48 Mil) to Sep. 2022 ($4.42 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Pharmagreen Biotech's Enterprise Value for Today is $0.99 Mil.
Pharmagreen Biotech Market Cap Historical Data
The historical data trend for Pharmagreen Biotech's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Pharmagreen Biotech's Market Cap
For the Drug Manufacturers - Specialty & Generic subindustry, Pharmagreen Biotech's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmagreen Biotech's Market Cap Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pharmagreen Biotech's Market Cap distribution charts can be found below:
* The bar in red indicates where Pharmagreen Biotech's Market Cap falls into.
Pharmagreen Biotech Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Pharmagreen Biotech's Market Cap for the fiscal year that ended in Sep. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmagreen Biotech (OTCPK:PHBI) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Pharmagreen Biotech Market Cap Related Terms
Thank you for viewing the detailed overview of Pharmagreen Biotech's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Pharmagreen Biotech (Pharmagreen Biotech) Business Description
Pharmagreen Biotech Inc is a biotech science company with specialized products and services in the cannabis industry. The company plans to produce and sell tissue culture plantlets and cannabis oil. Its line of nutraceutical products is a proprietary blend of therapeutic plants and mushrooms. It is developing its business model beyond just cannabis, and is focused on near term revenues from its proprietary blend of therapeutic plants and fungi, a nutraceutical wellness product. Utilizing the Company's expertise in plant genetics, Its transgenic program uses the newest technology available to research and create nutraceuticals, protein-based vaccines, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PHBI has been successfully added to your 